Wednesday, 28 February 2024
Trending

Investing

Roche partners with PathAI for AI diagnostics expansion By Investing.com

Thousands of Black women claim hair relaxers gave them cancer

© Reuters.

TUCSON, Ariz. – Roche Tissue Diagnostics (RTD) has entered into an exclusive collaboration with PathAI to develop artificial intelligence (AI) algorithms for digital pathology, a move aimed at enhancing precision medicine and expanding patient access to targeted treatments. These algorithms will be integrated into Roche’s navify Digital Pathology platform, used by pathology laboratories globally.

The partnership, announced today, positions PathAI as the sole external developer of AI-powered companion diagnostics algorithms for a set term, while Roche maintains the ability to develop its own. PathAI retains the freedom to develop algorithms outside of the companion diagnostics field.

Jill German, Head of Roche Tissue Diagnostics, emphasized the company’s leadership in companion diagnostics and its commitment to innovation in personalized healthcare. The collaboration is expected to meet the increasing demand from biopharma companies for AI-enabled companion diagnostics, providing a comprehensive solution for precision therapeutics.

Dr. Andy Beck, CEO and Co-Founder of PathAI, highlighted the shared goal of advancing digital pathology and AI diagnostics for drug development and clinical care. He noted that the integration of high-value diagnostic products into laboratory workflows will speed up the adoption of digital pathology, aiding clinicians in diagnosis and biomarker characterization.

Previously, in October 2021, Roche and PathAI developed an embedded image analysis workflow for pathologists, marking the first full integration of PathAI algorithms into the Roche Open Environment.

Roche, a global leader in in-vitro diagnostics and the largest biotechnology company, has a history of partnering with pharmaceutical companies to develop predictive diagnostics and advance precision medicine. The company’s expertise in digital pathology and AI-based image analysis is expected to facilitate the delivery of critical therapies to patients.

This strategic partnership is based on a press release statement.

InvestingPro Insights

As Roche Tissue Diagnostics forges ahead with its groundbreaking collaboration with PathAI, the company’s financial metrics underscore its strong position in the market. Roche Holding AG (OTC:) (RHHBY) shows resilience with a hefty market capitalization of $217.49 billion, indicating its significant footprint in the pharmaceutical industry. The company’s commitment to innovation in personalized healthcare is also…

Click Here to Read the Full Original Article at All News…